Compare

Bachem Holding AG/€BANB

1D1W1MYTD1Y5YMAX

About Bachem Holding AG

Bachem Holding AG is a Swiss-based company specializing in the development and manufacturing of peptides and oligonucleotides, primarily serving the pharmaceutical and biotechnology industries. With its expertise in this niche area, Bachem offers products including active pharmaceutical ingredients (APIs) and research chemicals. Founded in 1971, the company has positioned itself as a key supplier for both commercial and clinical-stage clients. Bachem has production sites in Switzerland, Germany, the United Kingdom, and the United States, allowing for a robust global presence. The company's strategic positioning benefits from its focus on high-quality, innovative manufacturing processes that comply with stringent regulatory standards.
Ticker
€BANB
Sector
Health
Primary listing
XGAT
Employees
2,725
Headquarters
Bubendorf, Switzerland
Website
www.bachem.com

BANB Metrics

BasicAdvanced
€6.4B
40.10
€2.13
0.79
€0.98
0.58%

Bulls say / Bears say

Bachem reported H1 2026 sales growth of 7.3% in local currencies and reaffirmed full-year local-currency sales growth of 35–40%, suggesting a strong expected second half. (Bachem)
Building K has entered operation and is already manufacturing commercial GMP products, adding large-scale peptide and oligonucleotide capacity that can support Bachem’s shift toward higher-volume commercial manufacturing. (Bachem; Bachem)
The Sisslerfeld project is backed by an agreement to supply large peptide volumes, including prepayments and long-term commitments, which should improve demand visibility and planning security beyond 2030. (Bachem)
H1 2026 EBITDA fell 9.0% year over year and the EBITDA margin declined to 25.4% from 29.1%, as Building K ramp-up costs weighed on profitability. (Bachem)
Commercial API revenue dropped 21.0% year over year in H1 2026, partly offsetting strong CMC Development growth and highlighting near-term mix and execution risk. (Bachem)
Bachem is entering a capital-intensive phase: it plans CHF 350–400 million of 2026 investment, while the Sisslerfeld project requires more than CHF 500 million and is supported by a CHF 500 million revolving credit facility, increasing financing and execution risk. (Bachem; Bachem; Bachem)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.

BANB Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

BANB Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.